Track topics on Twitter Track topics that are important to you
Lloyd Klickstein has joined resTORbio (NASDAQ: TORC) as chief scientific officer. Klickstein comes to Boston-based resTORbio from the Novartis Institutes for Biomedical Research (NIBR), where was glob...
resTORbio (NASDAQ:TORC) has announced the closing of a previously announced underwritten public offering of 7.2 million shares of its common stock at a price of US$6.95 per share. As quoted in the pre...
US-based biopharmaceutical firm resTORbio has commenced a Phase Ib/IIa clinical trial of its RTB101 candidate as a monotherapy or combination...Read More... The post resTORbio launches trial of RTB101...
resTORbio has commenced the Phase III PROTECTOR clinical programme to assess RTB101 to treat clinically symptomatic respiratory illness in elderly...Read More... The post resTORbio launches Phase III ...
ResTORbio Inc. (developing therapies to prevent or treat age-related diseases) netted $47mm through the follow-on public offering of 7.2mm common shares at $6.95 each. The company will use some of the...
resTORbio (NASDAQ:TORC) has announced it has finished enrolling patients in the Phase 3 PROTECTOR 1 trial ahead of schedule. As quoted in the press release: PROTECTOR 1 is the first of two global Phas...
Last year, resTORbio announced the positive results of its phase 2b hum
resTORbio, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. r...
We have published hundreds of resTORbio, Inc. news stories on BioPortfolio along with dozens of resTORbio, Inc. Clinical Trials and PubMed Articles about resTORbio, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of resTORbio, Inc. Companies in our database. You can also find out about relevant resTORbio, Inc. Drugs and Medications on this site too.